Healthy Living Clinic Tirzepatide Review

Healthy Living Clinic has real clinicians attached to it and a LegitScript certification, and it still sells GLP-1 medication in an order that we think is the wrong way round. Our research (September 1, 2026) found a compounded semaglutide and tirzepatide operation whose commercial structure and marketing language both warrant caution.

The Consultation Happens After You Pay

This is the central finding, and the clinic states it plainly on both medication pages:

"After checkout, you will have a consultation with a board-certified doctor licensed in your state. He or she will ask you a few questions to make sure you're eligible, and then you will receive your medications. Don't worry, it's as easy as 1, 2, 3."

A prescribing decision should determine whether money changes hands, not follow it. Once a patient has paid, both parties are working against a commercial expectation that the answer will be yes, and the patient has to seek a refund to act on a "no." The clinic does not publish refund terms for patients found ineligible at that consultation. The homepage compounds the impression with a speed claim:

"Get your prescription approved in minutes by board certified doctors and medical professionals without the inconvenience, expense, or embarrassment of going to the doctor's office."

"Approved in minutes" describes a throughput target, not a clinical standard.

Eligibility Is Set Below the Approved Indication

"Our program is designed specifically for individuals aged 18+ with a BMI of 25 or higher."

BMI 25 is the threshold for overweight. The approved indication for these medications in weight management is a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. A BMI 25 floor with no stated comorbidity requirement admits patients for whom this class of drug is not indicated, and it is a materially lower bar than Bold applies for the same drug class.

The Pricing Is Not Consistent Across the Site

The semaglutide page states:

"For $149/month, you will receive everything you need to take your first month of Semaglutide."

A separate GLP-1 page invites patients to start "for just $99/month." Two different entry prices on the same site, neither reconciled, and no published tier structure showing what a therapeutic dose costs at month six. The tirzepatide page carries no published price at all.

The $500 Bonus Stack

New customers are offered "over $500 in free bonuses": a fat-loss program valued at $250, recipes at $57, meal planning at $100, a goal planner at $60, workout videos at $47 and a dessert collection at $47. The fat-loss program is described as "helping people lose weight FAST for over 30 years." This is direct-response infomercial construction — inflated notional values assigned to digital content and totalled into a headline number — applied to a prescription drug purchase. It is not illegal and it is not evidence of harm, but it is a marketing grammar borrowed from supplement selling, and it sits awkwardly beside a medication carrying a boxed warning.

Tirzepatide Microdosing

The clinic sells "Tirzepatide – Microdosing" as a distinct product line. Microdosing GLP-1s is not an approved protocol and is not supported by the trial evidence that established these drugs' efficacy and safety profile. It may be a reasonable individualised clinical choice in specific circumstances; sold as a catalogue item it is something to question rather than assume.

Who Is Actually Behind It

To the clinic's credit, it names its clinical structure:

"The Healthy Living Clinic partners with Beluga Health, P.A., a Florida-based professional corporation located at 1321 Upland Dr., Suite 18399, Houston, TX 77043. Dr. Jonah Mink, MD, is our Chief Medical Officer and is licensed to practice in all 50 states and the District of Columbia."

Dr. Gregory Smith is named as Supervising Medical Director and Dr. Patrick Conrad as a board-certified MD. Beluga Health is a separate telehealth entity we have reviewed independently. Note the address as published describes a Florida corporation at a Texas address — a small inconsistency, but the kind worth noticing on a page meant to establish corporate identity.

What Is Not Published

No named pharmacy and no 503A or 503B status — only that medication is "made in America by an FDA-inspected compounding pharmacy." No refund policy for patients declined at the post-checkout consultation, no lab requirements, no dosing or titration protocol, no monitoring schedule, no tirzepatide pricing, no founding year, and no reconciliation of the $99 and $149 figures. The FAQ describes prescribing "FDA-approved and non FDA-approved compounded GLP-1 medications," which conflates two quite different things in a single sentence.